Company intelligence / Profile preview

ViroMed Co., Ltd.

Seoul, Seoul, South Koreaviromed.de ↗

Ownership: Private
Employees: ~9
Development stage: Phase 3

Overview

ViroMed has advanced its lead candidate, VM202, a gene therapy delivering the HGF gene via intramuscular injection, into late-stage clinical trials for diabetic peripheral neuropathy and other indications. The company has a total of eight projects in clinical stages across the US, Korea, and China. Early results have shown promise in treating chronic and incurable diseases such as diabetic foot ulcers and ALS.

Therapeutic areas: OncologyEndocrinologyCardiovascularNeurology
Modalities: Gene therapyNovel biologicsBotanical therapeutics
Industry: Biotech

Drug pipeline

5 assets

VM-206RY

4 more assets in the full pipeline.

Request access →

Partnerships

Reyon Pharm. (Korea)PMG Pharm. (Korea)Beijing Northland Biotech (China)Yuhan Corporation

Beyond the preview

Go deeper on ViroMed Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ViroMed Co., Ltd..

Explore the full profile